Strengthening the Earnings Base Toward the Fiscal Year Ending May 2018
First written in FY2016. 1 of 3 entries say "Restated". Latest entry: FY2018.
The whole theme swung hardest in 2025: 1 of 9 companies on the "Worse" side.
1 other company's latest entry also says "Achieved".
- FY2018AchievedAnnual report
「Net sales for the fiscal year ended May 2018 were ¥54,562 million, exceeding the target.」
The company achieved the medium-term management plan target of consolidated net sales of at least ¥52.5 billion for the fiscal year ended May 2018, reporting ¥54,562 million. - FY2017RestatedAnnual report
「Regarding the management indicators targeted by the group on a consolidated basis, its basic policy under the medium-term management plan “Challenge 2017—Entering the Self-Medication Support Business and Aiming to Become a Chosen Company,” announced on 14 July 2015, set a target of consolidated net sales of at least ¥52.5 billion for the fiscal year ended May 2018.」
The medium-term management plan explicitly set a target of consolidated net sales of at least ¥52.5 billion for the fiscal year ended May 2018. - FY2016First statedAnnual report
「To strengthen the earnings platform for the second half of the fiscal year and the fiscal year ended May 2018」
The company plans to particularly intensify efforts to establish family pharmacist and pharmacy services and strengthen its future earnings platform.